Ex vivo activated immune cells
Phase 1/Phase 2- Indications
- Aplastic anemia
Company intelligence / Profile preview
Shenzhen Zhongxing Yangfan Bio-Engineering Co Ltd
Shenzhen, Guangdong Sheng, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Shenzhen Zhongxing Yangfan Bio-Engineering Co Ltd has developed a small molecule drug, hematoporphyrin ether ester, currently in Phase 3 clinical trials for esophageal carcinoma. The company previously investigated this compound for chronic bronchitis but that indication appears inactive. No additional pipeline programs are publicly disclosed[6].
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shenzhen Zhongxing Yangfan Bio-Engineering Co Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Zhongxing Yangfan Bio-Engineering Co Ltd.